CONX Corp.
CONX Corp. filed an 8-K under Item 4.02 disclosing non-reliance on its previously issued consolidated statement of cash flows for the year ended December 31, 2024. Management identified a misclassification of interest income on cash-equivalent investments that overstated operating cash outflows and understated investing cash outflows by approximately $5.9 million each. The restatement has no impact on net income, EPS, or the balance sheet, but the audit committee concluded the error was material to the cash flow statement and the 2024 10-K should no longer be relied upon.
- Item 4.02: CONX Corp. concluded its 2024 consolidated statement of cash flows should no longer be relied upon.
- Error involved misclassification of interest income on cash-equivalent investments between operating and investing activities.
- Restatement flips 2024 operating cash flow from -$4.9M to +$1.0M and increases investing cash outflow by ~$5.9M.
- No impact on net income, EPS, total assets, liabilities, equity, or cash and equivalents.
- Audit committee and auditor WithumSmith+Brown consulted; restated 2024 cash flows to appear in the 2025 10-K.
Price data unavailable.
An Item 4.02 non-reliance filing is among the highest red-flag 8-K disclosures; for an OTC-traded SPAC, a material cash-flow restatement raises serious questions about financial controls.
SPACs trading on OTC markets already face credibility headwinds; a cash-flow restatement — even one with no P&L impact — further erodes investor confidence and may complicate any pending or future business combination.
The restatement signals a material weakness in internal controls over financial reporting for cash flow classification. As a SPAC trading OTC, CONX faces heightened scrutiny; any further control deficiencies could delay the 2025 10-K or impair merger prospects.